Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities
Journal of Biochemical and Molecular Toxicology · 2025
DOI: 10.1002/jbt.70427 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Jing Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Fourth People's Hospital of Jinan, Jinan, China. Hauptthemen laut MEDLINE: Neoplasms, Proteolysis, Antineoplastic Agents, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 138 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Cancer ranks as the second leading cause of mortality around the globe, only behind cardiovascular ailments, largely owing to challenges in early detection and a significant recurrence rate following standard treatments. Chemotherapy is effective in suppressing the swift proliferation of malignant cells; however, it also adversely impacts normal cells that replicate quickly. Consequently, it is essential to create alternative and safer treatment approaches that are more efficient. The intracellular ubiquitin‐proteasome system for targeted protein destruction is an emerging technology in the development of therapeutic agents for personalized medicine. Proteolysis targeting chimeras (PROTACs), composed of two compounds that bind to a target protein and an E3 ubiquitin ligase, have offered promising strategies in the treatment of multiple cancers. PROTACs have shown potential in overcoming resistance mutations by degrading cancer‐associated proteins, including resistant variants, while requiring only low concentrations within cells. The present article reviews the biochemical structure of PROTAC and highlights PROTAC technology in the treatment of cancer. The application of PROTACs in targeting main cancer‐related proteins, including Kirsten rat sarcoma virus (KRAS), epidermal growth factor receptor (EGFR), and anaplastic lymphoma kinase (ALK) mutations, has demonstrated promising approaches in the effective treatment of cancer in preclinical models. Additionally, the review provides hints at the current advances in the PROTAC technology for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Fourth People's Hospital of Jinan, Jinan, China.
- Department of Respiratory and Critical Care Medicine, Fourth People's Hospital of Jinan, Jinan, China.
ORCID-Profile: Boshu Yin
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Yang, J., Qiao, Q., Lin, N., Niu, M., Su, L., & Yin, B. (2025). Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70427
Vancouver
Yang J, Qiao Q, Lin N, Niu M, Su L, Yin B. Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70427
BibTeX
@article{Yang2025,
author = {Yang, Jing and Qiao, Qing and Lin, Na and Niu, Miaomiao and Su, Lin and Yin, Boshu},
title = {Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
doi = {10.1002/jbt.70427}
}
EUVIMED